Rejuran S/I: Understanding Regulatory Status for Professional Sourcing

Rejuran S and Rejuran I are polynucleotide (PN) formulations manufactured by Pharma Research, a South Korean company. These products are positioned within the skinbooster and biostimulator categories, distinct from traditional dermal fillers. Their core ingredient, polynucleotides, derived from salmon DNA, are designed for specific applications in aesthetic medicine. The origin from South Korea places their initial regulatory pathway under the jurisdiction of the Korean Ministry of Food and Drug Safety (KFDA).

As a product of South Korean origin, Rejuran S/I initially undergoes approval by the KFDA. This national certification confirms its manufacturing quality and intended use within South Korea. For international distribution, further certifications are often required. The CE Mark indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area. [VERIFY: Specific Rejuran S/I CE Mark status for each product variant, if applicable for the intended market].

Regarding the United States, FDA approval is a distinct and rigorous process. [VERIFY: Current FDA approval status for Rejuran S/I for aesthetic use in the US market]. Professionals sourcing products must distinguish between approvals for specific indications versus general market clearance.

Accessing Rejuran S/I for clinics in the European Union and the United Kingdom requires understanding local regulations. The presence of a CE Mark is generally a prerequisite for medical devices and aesthetic products within the EU. However, individual member states may have additional national registration or import requirements. The UK, following its departure from the EU, maintains its own regulatory framework, often aligning with but potentially diverging from EU standards. For a broader range of similar products, review options in the skinbooster / biostimulator catalog.

Markets in the Gulf Cooperation Council (GCC) countries, Latin America (LATAM), and the broader Asia-Pacific (APAC) region each possess unique regulatory frameworks. These often involve national health authority registrations, local agent requirements, and specific import licenses. For example, countries like the UAE, Saudi Arabia, Brazil, Mexico, and Australia each have independent processes. [VERIFY: Rejuran S/I specific registration status in key GCC, LATAM, and APAC markets]. Professionals should consult local regulatory bodies or expert legal counsel to ensure full compliance for their sourcing activities. Products like AMI Eyes, also a polynucleotide-based solution, navigate similar regulatory pathways in these regions.

Parallel importing involves sourcing original products from a country where they are legally marketed, and then importing them into another country without the consent of the manufacturer's authorized distributor in the destination market. While the products themselves are genuine, the legality of parallel imports for aesthetic injectables can vary significantly by national jurisdiction. Professionals must understand that regulatory bodies often have strict rules concerning product traceability, labeling, and quality control that may be compromised by unofficial supply chains. Always verify the legality of parallel imports in your specific region to avoid complications. For additional insight into authentic product sourcing, consider reviewing our guide on How Professionals Can Verify Genuine Onetox 200 Units.

To ensure regulatory compliance and patient safety, clinics must demand specific documentation from their Rejuran S/I suppliers. Key certifications include: a Certificate of Authenticity from the manufacturer or authorized distributor, lot numbers verifiable against the manufacturer's records, and proof of cold chain integrity during transport. Suppliers should also be able to provide evidence of their own licensing and adherence to Good Distribution Practices (GDP). This due diligence helps mitigate risks associated with counterfeit products, improper storage, or unapproved versions. Understanding the Meditoxin 200unit: Understanding Its Regulatory Status for P provides additional context on the importance of verifying product documentation across different injectable categories.